While yet to be evaluated, it is currently unknown how such observations may extend to more recently proposed preclinical targets, such as SOCS family member CISH, shown to suppress both NK [235] and cytotoxic T [236] cell activity in tumor-bearing mice, which, when knocked out, can enhance antitumor immune function. This evidence concerns the gene CISH and neoplasm.